P3, N=511, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

This study uncovered that lenvatinib could be a potent ICD inducer, which could trigger ERS via increasing ROS levels in HCC cells, which present valuable insights into the mechanism of lenvatinib-induced ICD in HCC cells. Collectively, our findings highlight the significant therapeutic potential of the combination of targeting GPX2 and treatment with lenvatinib for HCC.

P3, N=112, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

TIL counts, including those of CD3+ and CD8+ TILs, in the peritumoral area were significantly higher after ATZ/BEV than after LEN therapy.

P2, N=59, Not yet recruiting, Eastern Hepatobiliary Surgery Hospital | Trial completion date: Apr 2028 --> Apr 2029

P3, N=170, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting

Taken together, SNRPA promotes HCC growth and lenvatinib resistance via B7-H6-STAT3/AKT axis through facilitating B7-H6 pre-mRNA maturation by maintaining its intron 2 splicing. Thus, SNRPA may be a promising target for HCC therapy and lenvatinib resistance reversion.

To the best of our knowledge, this is the first report of SJS caused by selpercatinib. We herein present and discuss this case to raise awareness.

P4, N=50, Active, not recruiting, Eisai Pharmaceuticals India Pvt. Ltd | Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Dec 2024 --> Apr 2025

The combination therapy was manageable in terms of safety and toxicity, with a predictable safety profile. These findings suggest that lenvatinib and eribulin represent a promising treatment strategy for advanced, heavily pretreated solid tumors, warranting further exploration in larger clinical studies.

In conclusion, this study provides an experimental foundation for targeted drug therapy in HCC and offers novel insights, perspectives, and methodologies for understanding the development and occurrence of this disease. These findings are significant for the development of new diagnostic and therapeutic markers for HCC, with the ultimate goal of reducing drug resistance.

P2, N=104, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2025 --> Feb 2028 | Trial primary completion date: Apr 2025 --> Feb 2028

P1, N=36, Completed, Eli Lilly and Company | N=25 --> 36

In an observational retrospective real-world database study, immune checkpoint inhibitors were used in 14.7% of patients with advanced or recurrent endometrial cancer across multiple lines of treatment, including after initial immune checkpoint inhibitor treatment.

Between May 2010 and October 2021, 255 consecutive patients with LHCC receiving conversion therapy of TACE combined with Lenvatinib plus PD-1 inhibitors were included from three tertiary-care hospitals...Two prognostically distinct risk strata were identified according to these nomograms (all P < 0.001). Based on 255 patients receiving TACE combined conversion therapy for LHCC, we developed and validated two nomograms for predicting OS, with superior performances than five major staging systems and effective survival stratification.

P2, N=56, Active, not recruiting, Yale University | Recruiting --> Active, not recruiting

P2, N=46, Recruiting, Fundación GECP | N=85 --> 46

LT combined with magnetic hyperthermia increased CTLs, reduced Tregs, decreased immunosuppressive cytokines, and elevated pro-inflammatory ones, collectively initiating a strong antitumor immune response. LT combined with magnetic hyperthermia showed superior antitumor effect compared to either treatment alone.

P2, N=74, Not yet recruiting, Fudan University

P=N/A, N=238, Completed, Second Affiliated Hospital of Guangzhou Medical University

P3, N=107, Completed, Merck Sharp & Dohme LLC | N=27 --> 107

P2, N=92, Recruiting, Fudan University | Not yet recruiting --> Recruiting

The patient received six months of oxaliplatin plus gemcitabine (GEMOX), lenvatinib, and toripalimab, achieving significant tumor regression. The combination of GEMOX, lenvatinib, and toripalimab is an effective and safe conversion therapy regimen. This approach may serve as a model for managing similar advanced cases.

P1/2, N=25, Active, not recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Active, not recruiting | Trial completion date: Jul 2027 --> Apr 2027 | Trial primary completion date: Dec 2026 --> Apr 2027

This case underscores the need for personalized approaches in treating AM, especially those with rare molecular alterations like AGK-BRAF fusion. Insights from genomic and immune profiling may inform future therapeutic strategies to overcome resistance and improve outcomes in this challenging melanoma subtype.

Our study provided a delicate immune landscape of anti-PD-1and Lenvatinib combination, and we also offered scientific evidences that TACE-Len-PD-1 triple therapy could fulfill better clinical benefits than TACE-Len dual therapy, which is anticipated to provide objective and effective evidences for clinical use.

Furthermore, compound 15a significantly inhibited the growth of patient-derived HCC xenografts in nude mice with greater efficacy than the multi-kinase inhibitor lenvatinib. The promising efficacy and good biosafety profile of compound 15a enables us to further develop this compound for treating patients with HCC and possibly other cancers in clinic.

Moreover, high expression of STX6 displayed low preventive efficacy of lenvatinib as a postoperative adjuvant treatment for HCC patients with a high risk of recurrence. Collectively, we identified that STX6-mediated autophagy plays a crucial role in lenvatinib resistance in HCC, providing a potential therapeutic target to overcome lenvatinib resistance for HCC patients.

P=N/A, N=32, Not yet recruiting, The Third Affiliated Hospital Sun Yat-sen University; The Third Affiliated Hospital Sun Yat-sen University

P=N/A, N=78, Not yet recruiting, Second Affiliated Hospital of Guangzhou Medical University; Second Affiliated Hospital of Guangzhou Medical University

P=N/A, N=205, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University

P3, N=156, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

P2, N=59, Recruiting, The Third Affiliated Hospital of Naval Medical University; The Third Affiliated Hospital of Naval Medical University

Two highly potent and selective RET small-molecule inhibitors, selpercatinib and pralsetinib, were granted accelerated approval for advanced RET fusion-positive NSCLC by the US Food and Drug Administration, and have been shown to be highly effective both in treatment-naive and previously treated patients with NSCLC. Selpercatinib has shown superiority over chemotherapy in a phase 3 study (LIBRETTO-431) in previously untreated patients with RET fusion-positive NSCLC, which established its place as the standard of care in this patient population. This review discusses the biology and clinical characteristics of RET-rearranged NSCLC and summarizes the evolution of treatment strategies, current understanding of mechanisms of resistance, and development of new-generation agents to overcome resistance.

P=N/A, N=60, Not yet recruiting, Tianjin Third Central Hospital; Tianjin Third Central Hospital

P=N/A, N=110, Not yet recruiting, The Third Affiliated Hospital of Naval Medical University; The Third Affiliated Hospital of Naval Medical University

P=N/A, N=200, Not yet recruiting, Affiliated Hospital of Guangdong Medicine University; Affiliated Hospital of Guangdong Medicine University

P2, N=276, Not yet recruiting, the First Affiliated Hospital of Nanjing Medical University; the First Affiliated Hospital of Nanjing Medical University

P3, N=708, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2026 --> Feb 2027

Deescalation of therapy was the aim of low-dose versus standard-dose Pembrolizumab in advanced NSCLC. Preliminary data in thymic epithelial tumors (TET) and immune-checkpoint-inhibitor (ICI) therapy in combination with Lenvatinib were presented in the PECATI trial.

P2, N=320, Not yet recruiting, Second Affiliated Hospital of Guangzhou Medical University

HDRI, in combination with lenvatinib, demonstrated potential benefits in radioiodine-avid metastatic WDTC. The combination treatment was well-tolerated. There was an unprecedented fall in tumor marker level and partial response on imaging by a single cycle of the therapy. While a small sample size limited the study, preliminary data suggest that the synergistic effect may improve disease control. Further investigation with a larger cohort is warranted to confirm findings and explore potential response predictors.